A Synthetic ERR Agonist Alleviates Metabolic Syndrome

Cyrielle Billon, Emmalie Schoepke, Amer Avdagic, Arindam Chatterjee, Andrew A. Butler, Bahaa Elgendy, John K. Walker, Thomas P. Burris

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Physical exercise induces physiologic adaptations and is effective at reducing the risk of premature death from all causes. Pharmacological exercise mimetics may be effective in the treatment of a range of diseases including obesity and metabolic syndrome. Previously, we described the development of SLU-PP-332, an agonist for the estrogen-related receptor (ERR)a, b, and c nuclear receptors that activates an acute aerobic exercise program. Here we examine the effects of this exercise mimetic in mouse models of obesity and metabolic syndrome. Diet-induced obese or ob/ob mice were administered SLU-PP-332, and the effects on a range of metabolic parameters were assessed. SLU-PP-332 administration mimics exercise-induced benefits on whole-body metabolism in mice including increased energy expenditure and fatty acid oxidation. These effects were accompanied by decreased fat mass accumulation. Additionally, the ERR agonist effectively reduced obesity and improved insulin sensitivity in models of metabolic syndrome. Pharmacological activation of ERR may be an effective method to treat metabolic syndrome and obesity.

Original languageEnglish
Pages (from-to)232-240
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume388
Issue number2
DOIs
StatePublished - Feb 1 2024

Fingerprint

Dive into the research topics of 'A Synthetic ERR Agonist Alleviates Metabolic Syndrome'. Together they form a unique fingerprint.

Cite this